December 18, 2023
PassPort Technologies, Inc.

PassPort Technologies Commences Collaborative Research with Arcturus
Therapeutics to Evaluate Transdermal mRNA delivery systems
Arcturus’s mRNA medicines and vaccines and lipid-mediated drug delivery systems incombination with PassPort’s innovative transdermal drug delivery system.

PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in California,
USA is pleased to announce the initiation of a collaborative research endeavor with Arcturus
Therapeutics (ARCT). This research collaboration is focused on evaluating innovative mRNA
formulations and transdermal delivery mechanisms for vaccines and therapeutics.
The research collaboration will leverage ARCT’s expertise in mRNA design and proprietary
LUNAR® platform technologies, alongside PPTI’s groundbreaking PassPort® transdermal drugdelivery technology. PPTI will utilize its unique platform technology and extensive knowledge intransdermal biologics and oligonucleotides delivery. ARCT will supply select mRNA and LUNAR®
formulations, which PPTI will subsequently adapt to the PassPort® system.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings
Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company withenabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturusdeveloped Kostaive™, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in theworld to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccineswith CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNAvaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentiallytreat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA
therapeutics platforms can be applied toward multiple types of nucleic acid medicines including
messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA,and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio(patents and patent applications issued in the U.S., Europe, Japan, China, and other countries).

For more information, visit www.ArcturusRx.com. In addition, please connect with us
on Twitter and LinkedIn.
About PassPort Technologies, Inc.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patientdelivery of exceptional pharmaceuticals through the PassPort system. The company aims toconstantly develop technologies that serve not only the pharmaceutical industry but also broader
life sciences sectors. PPTI’s mission is to advance global health outcomes. Further details can befound at https://passport-tech.com.
About PassPort® Technology
The PassPort® System integrates microporation technology to painlessly form micropores inthe skin seamlessly and a patch formulation technology that regulates drug delivery through thesemicropores. This innovative system now enables transdermal delivery of biologics andoligonucleotides, which were previously limited to injections and infusions.

■For inquiries regarding this matter, please contact:

PassPort Technologies, Inc.
Hirotoshi Adachi, Ph.D.
Chief Operating Officer
5580 Morehouse Drive, Suite 120, San Diego, CA 92121, USA
TEL: +1-858-888-4188
E-mail: info@passport-tech.com
URL: https://passport-tech.com/